Arindam Dhar

An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients

Nicole G. Chau, Clement Ma, Kristina Danga et al. · JNCI Cancer Spectrum · 2019 · 225 citations · Full text

Medicine, Genetics, Oncology +17

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

Sarina A. Piha‐Paul, Christine L. Hann, Christopher A. French et al. · JNCI Cancer Spectrum · 2019 · 207 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia

Charles C. Bell, Katie Fennell, Yih-Chih Chan et al. · Nature Communications · 2019 · 180 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

Timothy A. Yap, Jane N. Winter, Lisa Giulino‐Roth et al. · Clinical Cancer Research · 2019 · 164 citations · Full text

Medicine, Oncology, Pharmacology +13

The role of AP-1, NF-κB and ROS/NOS in skin carcinogenesis: The JB6 model is predictive

Arindam Dhar, Mathew R. Young, Nancy H. Colburn · Molecular and Cellular Biochemistry · 2002 · 155 citations

Medicine, Dermatology, Oncology +14